Alexion turns focus to rebuilding pipeline amid restructuring; Pharma wades into the world of virtual reality marketing; FDA knocks back Novartis' Advair copy; Biogen drops Tysabri stroke program after Phase 2 miss
Rejection of the generic will give GSK some breathing room as it prepares to absorb the financial hit of losing patent protection for the blockbuster asthma drug.
BROUGHT TO YOU BY – Syneos Health Commercial Trends for Biopharma in 2018
As consolidation blurs boundaries between IDNs, health insurers and retail pharmacies, leaders will plunge into healthcare AI, seek out new influencers, bet on value-based contracts, and purchase more services from contract commercial organizations (CCOs). For more on these trends, click here.
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.